PF-Atlas › Clinical Trials › NCT06736990
A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis
CAL101 · Phase 2
Registry ID
NCT06736990
Phase
Phase 2
Status
Active, not recruiting
Drug / intervention
CAL101
Sponsor
Calluna Pharma AS
Start
2025-06-20
Enrollment
150
Locations
54
About this trial
The goal of this clinical trial is to learn if the investigational drug CAL101 can help prevent further decline in lung function in adults with Idiopathic Pulmonary Fibrosis. Researchers will compare CAL101 with placebo to compare change from baseline in forced vital capacity (FVC). Participants will be randomly assigned to a study group that will receive an IV infusion of either the study medication or placebo about once a month for 6 months.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT06736990 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.